184 related articles for article (PubMed ID: 3130270)
1. N-0437: a selective D-2 dopamine receptor agonist in in vitro and in vivo models.
Van der Weide J; De Vries JB; Tepper PG; Krause DN; Dubocovich ML; Horn AS
Eur J Pharmacol; 1988 Mar; 147(2):249-58. PubMed ID: 3130270
[TBL] [Abstract][Full Text] [Related]
2. The effects of kainic acid and 6-hydroxydopamine lesions, metal ions and GTP on in vitro binding of the D-2 dopamine agonist, [3H]N-0437, to striatal membranes.
Van der Weide J; De Vries JB; Tepper PG; Horn AS
Eur J Pharmacol; 1987 Nov; 143(1):101-7. PubMed ID: 3121365
[TBL] [Abstract][Full Text] [Related]
3. The enantiomers of the D-2 dopamine receptor agonist N-0437 discriminate between pre- and postsynaptic dopamine receptors.
Van der Weide J; Tendijck ME; Tepper PG; De Vries JB; Dubocovich ML; Horn AS
Eur J Pharmacol; 1988 Feb; 146(2-3):319-26. PubMed ID: 2836210
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological profile of N,N dipropyl-8-hydroxy-3-chromanamine, an oxygen isostere of the dopamine agonist N,N dipropyl-5-hydroxy-2-aminotetralin with enhanced presynaptic selectivity.
Vermue NA; Kaptein B; Tepper PG; de Vries JB; Horn AS
Arch Int Pharmacodyn Ther; 1988; 293():37-56. PubMed ID: 3421784
[TBL] [Abstract][Full Text] [Related]
5. Neuropharmacological profile of a new series of dopamine agonists: N-n-propyl-hexahydronaphthoxazines.
Hazelhoff B; De Vries JB; Dijkstra D; Mulder TB; Timmermans PB; Wynberg H; Horn AS
Eur J Pharmacol; 1986 May; 124(1-2):93-106. PubMed ID: 3720849
[TBL] [Abstract][Full Text] [Related]
6. The enantiomers of the dopamine agonist N-0437: in vivo and in vitro effects on the release of striatal dopamine.
Timmerman W; Dubocovich ML; Westerink BH; De Vries JB; Tepper PG; Horn AS
Eur J Pharmacol; 1989 Jul; 166(1):1-11. PubMed ID: 2572424
[TBL] [Abstract][Full Text] [Related]
7. Prejunctional inhibitory effect of a dopamine D-2 agonist, N-0437, on vascular adrenergic responses.
Friedman DJ; Budai D; Krause DN; Duckles SP
J Pharmacol Exp Ther; 1989 Sep; 250(3):853-9. PubMed ID: 2674420
[TBL] [Abstract][Full Text] [Related]
8. 7-[3-(4-[2,3-Dimethylphenyl]piperazinyl)propoxy]-2(1H)-quinolinone (OPC-4392), a presynaptic dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist.
Yasuda Y; Kikuchi T; Suzuki S; Tsutsui M; Yamada K; Hiyama T
Life Sci; 1988; 42(20):1941-54. PubMed ID: 3130534
[TBL] [Abstract][Full Text] [Related]
9. Rotational behavior induced by 8-hydroxy-DPAT, a putative 5HT-1A agonist, in 6-hydroxydopamine-lesioned rats.
Gerber R; Altar CA; Liebman JM
Psychopharmacology (Berl); 1988; 94(2):178-82. PubMed ID: 2965396
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of striatal dopamine release by the selective D-2 dopamine receptor agonist N-0437 is blocked by quinine.
Cass WA; Zahniser NR
Synapse; 1990; 5(4):336-7. PubMed ID: 2141733
[No Abstract] [Full Text] [Related]
11. Is TL-99 a selective presynaptic dopamine receptor agonist?
Horn AS; De Vries J; Dijkstra D; Mulder AH
Eur J Pharmacol; 1982 Sep; 83(1-2):35-45. PubMed ID: 7128699
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological profile of a chromanamine analogue (DP-6OH-3CA) of the selective presynaptic dopamine agonist N,N-dipropyl-7-hydroxy-2-aminotetralin.
Vermue NA; Dijkstra D; Horn AS
J Pharm Pharmacol; 1988 Aug; 40(8):574-7. PubMed ID: 2907015
[TBL] [Abstract][Full Text] [Related]
13. Interaction of the component enantiomers of the putative dopamine autoreceptor agonist, TL-99 (6,7-dihydroxy-2-dimethylamino tetralin) with dopaminergic systems in mammalian brain and teleost retina.
Williams M; Martin GE; McClure DE; Baldwin JJ; Watling KJ
Naunyn Schmiedebergs Arch Pharmacol; 1983 Dec; 324(4):275-80. PubMed ID: 6141532
[TBL] [Abstract][Full Text] [Related]
14. A pharmacological comparison of 6,7-dihydroxy-2-dimethylaminotetralin (TL-99) and N-n-propyl-3-(3-hydroxyphenyl)piperidine with (3-PPP) selected dopamine agonists.
Martin GE; Williams M; Haubrich DR
J Pharmacol Exp Ther; 1982 Nov; 223(2):298-304. PubMed ID: 6813451
[No Abstract] [Full Text] [Related]
15. Pharmacological profile of non-hydroxylated and ether derivatives of the potent D2-selective agonist N-0437.
Jansen JM; den Daas I; Rollema H; Swart PJ; Tepper PG; de Vries JB; Horn AS
Naunyn Schmiedebergs Arch Pharmacol; 1991 Feb; 343(2):134-42. PubMed ID: 1676829
[TBL] [Abstract][Full Text] [Related]
16. Further in vitro and in vivo studies with the putative presynaptic dopamine agonist N,N-dipropyl-7-hydroxy-2-aminotetralin.
Mulder TB; de Vries JB; Dijkstra D; Wiechers JW; Grol CJ; Horn AS
Naunyn Schmiedebergs Arch Pharmacol; 1987 Nov; 336(5):494-501. PubMed ID: 2830544
[TBL] [Abstract][Full Text] [Related]
17. N-methyl,N-propargyl-2-aminotetralins:novel dopamine agonists with monoamine oxidase inhibiting properties.
Hazelhoff B; De Vries JB; Dijkstra D; Mulder TB; Horn AS
Eur J Pharmacol; 1985 Feb; 109(2):229-40. PubMed ID: 3922776
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological profiles of three new, potent and selective dopamine receptor agonists: N-0434, N-0437 and N-0734.
Van der Weide J; De Vries JB; Tepper PG; Horn AS
Eur J Pharmacol; 1986 Jun; 125(2):273-82. PubMed ID: 3743637
[TBL] [Abstract][Full Text] [Related]
19. SCH 23390 may alter dopamine-mediated motor behaviour via striatal D-1 receptors.
Boyce S; Kelly E; Davis A; Fleminger S; Jenner P; Marsden CD
Biochem Pharmacol; 1985 May; 34(10):1665-9. PubMed ID: 2988552
[TBL] [Abstract][Full Text] [Related]
20. Relative selectivity of 6,7-dihydroxy-2-dimethylaminotetralin, N-n-propyl-3-(3-hydroxyphenyl)piperidine, N-n-propylnorapomorphine and pergolide as agonists at striatal dopamine autoreceptors and postsynaptic dopamine receptors.
Claustre Y; Fage D; Zivkovic B; Scatton B
J Pharmacol Exp Ther; 1985 Feb; 232(2):519-25. PubMed ID: 2857197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
